EUVIMEDEUVIMED entdecken
Fallbericht

Clinical emergence of a novel extended-spectrum variant deriving from the OXY-1 β-lactamase

Anne-Sophie Hong Tuan Ha, Alice Mammeri, Céline Plainvert, Rym Charfi, Claire Poyart, Asmaa Tazi, Hedi Mammeri

European Journal of Clinical Microbiology & Infectious Diseases · 2024

DOI: 10.1007/s10096-024-04922-8 ↗

Kurz gefasst

Fallbericht in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2024. Verfasst von Anne-Sophie Hong Tuan Ha und 6 weiteren Autor:innen. Beteiligte Einrichtung: Service de Bactériologie, Assistance Publique Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Site Cochin, 27 rue du Faubourg Saint-Jacques,…. Hauptthemen laut MEDLINE: beta-Lactamases, Ceftazidime, Drug Resistance, Multiple, Bacterial, Klebsiella. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The genomic comparison of two Klebsiella michiganensis clinical isolates recovered from the same patient, one resistant to piperacillin-tazobactam and intermediate to cefotaxime, the other resistant to ceftazidime but susceptible to piperacillin-tazobactam, revealed one mutation in the blaOXY-1-24 gene accounting for a L169M substitution in the Ω loop. Cloning experiment in Escherichia coli demonstrated the contribution of this mutation to the hydrolysis spectrum extension towards ceftazidime and cefepime, whereas the resistance to piperacillin-tazobactam was reduced. To the best of our knowledge, this study shows for the first time that ceftazidime resistance can occur in vivo from OXY-1 precursor by structural alteration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-LactamasesCeftazidimeDrug Resistance, Multiple, BacterialKlebsiellaHumansAnti-Bacterial AgentsEscherichia coliKlebsiella InfectionsMicrobial Sensitivity TestsMutationPiperacillin, Tazobactam Drug Combination

Stichwörter der Autor:innen

Klebsiella michiganensisBeta-lactamaseCefepimeCeftazidimeL169M substitutionOXY-1OXY-1-23OXY-1-24Piperacillin-tazobactam

Substanzen

Anti-Bacterial Agentsbeta-LactamasesCeftazidimePiperacillin, Tazobactam Drug Combination

Autor:innen und Institutionen

  • Service de Bactériologie, Assistance Publique Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Site Cochin, 27 rue du Faubourg Saint-Jacques, Paris, 75014, France.
  • INSERM, CNRS, Institut Necker Enfants Malades, Université Paris Cité, , Paris, 75015, France.
  • Institut Cochin, INSERM U1016, CNRS UMR8104, Université de Paris Cité, Paris, France.
  • Service de Bactériologie, Assistance Publique Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Site Cochin, 27 rue du Faubourg Saint-Jacques, Paris, 75014, France. hedi.mammeri@aphp.fr.
  • INSERM, CNRS, Institut Necker Enfants Malades, Université Paris Cité, , Paris, 75015, France. hedi.mammeri@aphp.fr.

Zitieren

APA

Hong Tuan Ha, A. S., Mammeri, A., Plainvert, C., Charfi, R., Poyart, C., Tazi, A., & Mammeri, H. (2024). Clinical emergence of a novel extended-spectrum variant deriving from the OXY-1 β-lactamase. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04922-8

Vancouver

Hong Tuan Ha AS, Mammeri A, Plainvert C, Charfi R, Poyart C, Tazi A, et al. Clinical emergence of a novel extended-spectrum variant deriving from the OXY-1 β-lactamase. European Journal of Clinical Microbiology & Infectious Diseases. 2024. doi:10.1007/s10096-024-04922-8

BibTeX
@article{HongTuanHa2024,
  author = {Hong Tuan Ha, Anne-Sophie and Mammeri, Alice and Plainvert, Céline and Charfi, Rym and Poyart, Claire and Tazi, Asmaa and Mammeri, Hedi},
  title = {Clinical emergence of a novel extended-spectrum variant deriving from the OXY-1 β-lactamase},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2024},
  doi = {10.1007/s10096-024-04922-8}
}
Kostenlos starten →